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Background: A diabetes risk score in Korean adults was developed and validated.
Methods: This study used the National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS) of 359,349 
people without diabetes at baseline to derive an equation for predicting the risk of developing diabetes, using Cox proportional 
hazards regression models. External validation was conducted using data from the Korean Genome and Epidemiology Study. 
Calibration and discrimination analyses were performed separately for men and women in the development and validation data-
sets.
Results: During a median follow-up of 10.8 years, 37,678 cases (event rate=10.4 per 1,000 person-years) of diabetes were identi-
fied in the development cohort. The risk score included age, family history of diabetes, alcohol intake (only in men), smoking sta-
tus, physical activity, use of antihypertensive therapy, use of statin therapy, body mass index, systolic blood pressure, total choles-
terol, fasting glucose, and γ glutamyl transferase (only in women). The C-statistics for the models for risk at 10 years were 0.71 
(95% confidence interval [CI], 0.70 to 0.73) for the men and 0.76 (95% CI, 0.75 to 0.78) for the women in the development datas-
et. In the validation dataset, the C-statistics were 0.63 (95% CI, 0.53 to 0.73) for men and 0.66 (95% CI, 0.55 to 0.76) for women.
Conclusion: The Korean Diabetes Risk Score may identify people at high risk of developing diabetes and may be an effective tool 
for delaying or preventing the onset of condition as risk management strategies involving modifiable risk factors can be recom-
mended to those identified as at high risk.
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INTRODUCTION
The increasing number of people with obesity has resulted in 
an increasing prevalence of diabetes in Korea [1]. Additionally, 
due to lower rates of both diabetes awareness and participation 
in health screening among young adults, it is important to iden-
tify at-risk asymptomatic individuals, especially in this age group.
Screening and early diagnosis of diabetes has considerable 
health benefits due to the ability to control glycemia and car-
diovascular risk factors [2]. Additionally previous clinical trials 
have indicated that interventions targeting lifestyle factors and 
diabetes medication with people with impaired glucose toler-
ance can prevent or delay the onset of diabetes [3,4]. However, 
many diabetes risk assessment tools were developed based on 
specific ethnic groups, and the risk scores may not apply to 
other ethnic groups [5,6]. Although a diabetes risk score for 
the Korean population was developed using the Korea Nation-
al Health and Nutrition Examination Survey (KNHANES), it 
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did not reflect the incidence of diabetes [7]. Lim et al. [8] also 
developed a risk score to predict the 4-year risk of diabetes us-
ing the Korean Genome and Epidemiology Study (KoGES); 
however, it was developed using a limited cohort size, the score 
did not take into account long-term outcome, and the sample 
might not be representative of the general population of Korea. 
The National Health Insurance Service-National Health 
Screening Cohort (NHIS-HEALS) was developed in 2002 as a 
random sample of 10% of the population between the ages of 
40 and 79 years who completed a national health screening test 
in 2002 or 2003 and who were followed up through 2013. We 
therefore developed a 10-year Korean Diabetes Risk Score (KDRS) 
using the NHIS-HEALS.
METHODS
Development and validation samples
We used the NHIS-HEALS to derive a diabetes risk equation. 
A detailed description of the study design and methods has 
been published previously [9]. In brief, the NHIS-HEALS co-
hort study enrolled 514,795 participants in 2002 or 2003. The 
database of this study contains demographic information, di-
agnoses, therapeutic procedures, drug prescriptions, date of 
death, and information from health examinations, such as 
health questionnaire surveys, physical examinations, and bio-
chemical test results. For this study, we excluded people with-
out variables used in the KDRS, people who had been diag-
nosed with diabetes (10th edition of the International Classifi-
cation of Diseases [ICD-10] codes E10–E14), and those with a 
self-reported medical history of diabetes or a fasting blood 
glucose level of 126 mg/dL or greater in 2002 or 2003. Thus, 
359,349 people were included at baseline. The incidence of dia-
betes was defined in terms of receiving a prescription for dia-
betes medication (Anatomical Therapeutic Chemical [ATC] 
code A10) or a fasting blood glucose level of 126 mg/dL or 
greater. The end of follow-up was the event of diabetes, death, 
or the end of the study period (December 31, 2013). Data on 
family history of diabetes, alcohol consumption, smoking sta-
tus, and physical activity were obtained from self-report ques-
tionnaires. Use of antihypertensive (ATC codes C02–C03 or 
C07–C09) and statin (ATC code C10AA) therapy was ascer-
tained based on drug prescriptions. Body mass index (BMI) 
was calculated as weight (kg) divided by height squared (m2) 
and classified according to Asian-specific criteria [10] as fol-
lows: underweight (<18.5 kg/m2), normal weight (18.5 to 22.9 
kg/m2), overweight (23.0 to 24.9 kg/m2), obese class I (25.0 to 
29.9 kg/m2), and obese class II (≥30.0 kg/m2). Fasting blood 
samples were taken to measure total cholesterol, glucose, and γ 
glutamyl transferase (GGT) levels.
The Ansung-Ansan Cohort Study, which is part of the KoG-
ES, was used for external validation. This population-based 
cohort was used in an epidemiological study of rural and ur-
ban communities in Korea. The baseline survey was completed 
in 2001 or 2002, and follow-up examinations are ongoing bien-
nially. A detailed description of the study design and methods 
has been published previously [11]. The Ansung-Ansan Co-
hort study enrolled 10,030 participants who were aged 40 to 69 
years in 2001 or 2002. We excluded people without variables 
used in the KDRS and people with diabetes. Diabetes was de-
fined as a fasting blood glucose level of ≥126 mg/dL, a 2-hour 
glucose level of ≥200 mg/dL in a 75-g oral glucose tolerance 
test, a glycosylated hemoglobin (HbA1c) level ≥6.5%, or a self-
reported medical history of diabetes. The end of follow-up was 
the event of diabetes or the last examination. Data on family 
history of diabetes, alcohol consumption, smoking status, phys-
ical activity, and use of drugs were obtained from self-report 
questionnaires. Height, weight, and blood pressure were mea-
sured using standardized techniques and equipment. Blood 
samples were obtained after fasting for at least 12 hours. 
Risk factors for diabetes
Our analysis included the following variables, which are known 
to affect diabetes risk: age (years), family history of diabetes 
(yes or no), alcohol intake (abstinent, low to medium, or high; 
only in men), smoking status (current, former, or non-smok-
er), physical activity (low, medium, or high), use of antihyper-
tensive therapy (yes or no), use of statin therapy (yes or no), 
BMI (<18.5, 18.5 to 22.9, 23.0 to 24.9, 25.0 to 29.9, or ≥30.0 
kg/m2), systolic blood pressure (<100, 100 to 119, 120 to 139, 
140 to 159, or ≥160 mm Hg), total cholesterol (<240 or ≥240 
mg/dL), fasting glucose (<70, 70 to 84, 85 to 99, 100 to 109, or 
≥110 mg/dL), and GGT level (continuous; only in women).
Statistical analysis
We used the Cox proportional hazards model in the develop-
ment dataset to estimate the coefficients and hazard ratios as-
sociated with each potential risk factor for the incidence of dia-
betes for men and women separately. The prognostic index, 
which is the sum of each coefficient multiplied by the confound-
er variable, was centered on the mean values of the risk factors 
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Table 1. Baseline characteristics of participants in development and validation cohorts at study entry
Variable
Development cohort Validation cohort
Men (n=191,199) Women (n=168,150) Men (n=3,164) Women (n=3,496)
Age, yr 51.2±9.2 52.5±9.6 50.4±8.4 51.3±8.8
Family history of diabetes 11,164 (5.8) 10,461 (6.2) 301 (9.5) 403 (11.5)
Alcohol intake
   Abstinent 66,159 (34.6) 138,003 (82.1) 960 (30.3) 2,597 (74.3)
   Low-medium 112,992 (59.1) 29,589 (17.6) 1,726 (54.6) 838 (24.0)
   High 12,048 (6.3) 558 (0.3) 478 (15.1) 61 (1.7)
Smoking status
   Non-smoker 79,056 (41.4) 161,964 (96.3) 658 (20.8) 3,321 (95.0)
   Former smoker 29,888 (15.6) 1,619 (1.0) 987 (31.2) 46 (1.3)
   Current smoker 82,255 (43.0) 4,567 (2.7) 1,519 (48.0) 129 (3.7)
Physical activity
   Low 95,495 (49.9) 112,770 (67.1) 2,539 (80.3) 2,921 (83.6)
   Medium 78,139 (40.9) 40,898 (24.3) 573 (18.1) 525 (15.0)
   High 17,565 (9.2) 14,482 (8.6) 52 (1.6) 50 (1.4)
Antihypertensive therapy 35,981 (18.8) 42,188 (25.1) 246 (7.8) 355 (10.2)
Statin therapy 6,124 (3.2) 7,454 (4.4) 18 (0.6) 9 (0.3)
Body mass index, kg/m2 23.9±2.8 23.9±3.0 24.2±2.8 24.7±3.2
Body mass index, kg/m2
   <18.5 4,588 (2.4) 3,927 (2.3) 62 (2.0) 47 (1.3)
   18.5–22.9 66,475 (34.8) 65,248 (38.8) 972 (30.7) 1,019 (29.2)
   23.0–24.9 53,976 (28.2) 44,110 (26.2) 907 (28.7) 893 (25.5)
   25.0–29.9 62,430 (32.7) 49,447 (29.4) 1,156 (36.5) 1,315 (37.6)
   ≥30.0 3,730 (2.0) 5,418 (3.2) 67 (2.1) 222 (6.4)
Systolic BP, mm Hg 128.0±17.2 124.2±18.5 120.6±16.6 118.2±18.8
Diastolic BP, mm Hg   81.0±11.4   77.2±11.8   81.4±10.9   77.4±11.5
Systolic BP, mmHg
   <100 2,823 (1.5) 7,005 (4.2) 226 (7.1) 489 (14.0)
   100–119 45,513 (23.8) 54,858 (32.6) 1,401 (44.3) 1,578 (45.1)
   120–139 91,123 (47.7) 68,943 (41.0) 1,135 (35.9) 944 (27.0)
   140–159 40,625 (21.2) 28,597 (17.0) 326 (10.3) 384 (11.0)
   ≥160 11,115 (5.8) 8,747 (5.2) 76 (2.4) 101 (2.9)
Total cholesterol, mg/dL 198.1±36.9 201.4±38.1 198.6±35.5 197.4±35.9
Total cholesterol, mg/dL
   <240 167,175 (87.4) 142,687 (84.9) 2,756 (87.1) 3,078 (88.0)
   ≥240 24,024 (12.6) 25,463 (15.1) 408 (12.9) 418 (12.0)
Fasting glucose, mg/dL 91.0 (82.0–101.0) 89.0 (81.0–98.0) 83.0 (78.0–90.0) 80.0 (76.0–85.0)
Fasting glucose, mg/dL
   <70 3,887 (2.0) 3,440 (2.0) 72 (2.3) 127 (3.6)
   70–84 55,142 (28.8) 54,681 (32.5) 1,654 (52.3) 2,431 (69.5)
   85–99 79,498 (41.6) 74,599 (44.4) 1,239 (39.2) 861 (24.6)
   100–109 32,794 (17.2) 23,564 (14.0) 160 (5.1) 61 (1.7)
   ≥110 19,878 (10.4) 11,866 (7.1) 39 (1.2) 16 (0.5)
GGT, U/L 32.0 (21.0–54.0) 16.0 (12.0–23.0) 31.0 (20.0–53.0) 15.0 (12.0–21.0)
Values are presented as mean±standard deviation, number (%), or median (interquartile range). 
BP, blood pressure; GGT, γ glutamyl transferase. 
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to derive a risk equation for a 10-year follow-up [12]. We did 
not consider the interaction terms between the independent 
variables. We tested the performance of the KDRS in the devel-
opment and validation dataset. Discrimination was evaluated 
by Harrell’s C-statistic [13]. Calibration (prediction accuracy) 
was assessed using a calibration plot comparing the observed 
probabilities (from the 10-year Kaplan-Meier estimates) with 
the predicted probabilities within deciles of predicted risk. The 
times to outcome events were visualized using Kaplan-Meier 
graphs according to confounding factors. The difference in the 
Kaplan-Meier curves between groups was assessed using the 
log-rank test. All analyses were conducted using the SAS soft-
ware version 9.4 (SAS Institute Inc., Cary, NC, USA).
Ethical consideration
The study protocol was reviewed and approved by the Ajou 
University Institutional Review Board (IRB) (IRB No. AJIRB-
MED-OBS-16-509). Review board requirements for written 
informed consent were waived because all personal identifying 
information was removed from the dataset prior to analysis.
RESULTS
Table 1 presents the characteristics of the men and women in 
both cohorts. In the development cohort, the mean±standard 
deviation (SD) age at baseline was 51.2±9.2 years in men and 
52.5±9.6 years in women. In the validation cohort, the mean±SD 
age at baseline was 50.4±8.4 years in men and 51.3±8.8 years 
in women. The median (interquartile range [IQR]) follow-up 
period was 10.8 years (IQR, 10.1 to 11.3 years) for the develop-
ment cohort and 9.5 years (IQR, 3.8 to 9.7 years) for the valida-
tion cohort. We identified 37,678 cases of diabetes arising from 
3,624,243 person-years (event rate=10.4 per 1,000 person-years) 
in the development cohort. In the validation cohort we identi-
fied 1,040 cases of diabetes from 46,028 person-years (event 
rate=22.6 per 1,000 person-years). 
Table 2 lists the results of the Cox regression analysis for the 
development dataset. The risk of diabetes was significantly high-
er among people with a family history of diabetes, high levels 
of alcohol consumption (only in men), and low levels of physi-
cal activity as well as among users of antihypertensive or statin 
therapy and former/current smokers. The risk of diabetes in-
creased with high BMI, systolic blood pressure, total cholester-
ol, or fasting glucose in men and women. In women, the risk 
increased with increasing GGT. People with fasting glucose 
Table 2. Adjusted hazard ratio (95% confidence interval) for 
diabetes in the development cohort
Variable Men Women
Age, yr 1.04 (1.03–1.04) 1.03 (1.03–1.04)
Family history of diabetes 1.50 (1.43–1.58) 1.57 (1.48–1.67)
Alcohol intake NA
   Abstinent 1.00 
   Low-medium 0.92 (0.89–0.95)
   High 1.06 (1.00–1.11)
Smoking status
   Non-smoker 1.00 1.00 
   Former smoker  1.07 (1.03–1.12) 1.27 (1.09–1.47)
   Current smoker 1.48 (1.43–1.52) 1.31 (1.21–1.42)
Physical activity
   Low 1.00 1.00 
   Medium 0.88 (0.86–0.91) 0.93 (0.90–0.97)
   High 0.87 (0.83–0.91) 0.98 (0.93–1.03)
Antihypertensive therapy 1.39 (1.35–1.44) 1.47 (1.42–1.52)
Statin therapy 1.30 (1.23–1.38) 1.37 (1.30–1.45)
Body mass index, kg/m2
   <18.5 1.08 (0.97–1.19) 1.01 (0.88–1.16)
   18.5–22.9 1.00 1.00 
   23.0–24.9 1.40 (1.35–1.45) 1.38 (1.32–1.45)
   25.0–29.9 1.92 (1.86–1.99) 1.91 (1.83–1.99)
   ≥30.0 3.50 (3.27–3.75) 2.90 (2.72–3.09)
Systolic BP, mm Hg
   <100 0.89 (0.76–1.03) 0.84 (0.74–0.95)
   100–119 1.00 1.00 
   120–139 1.16 (1.12–1.21) 1.21 (1.16–1.26)
   140–159 1.29 (1.24–1.35) 1.34 (1.28–1.41)
   ≥160 1.41 (1.33–1.49) 1.44 (1.35–1.53)
Total cholesterol, mg/dL
   <240 1.00 1.00 
   ≥240 1.20 (1.15–1.24) 1.11 (1.07–1.15)
Fasting glucose, mg/dL
   <70 0.94 (0.83–1.07) 0.98 (0.85–1.13)
   70–84 1.00 1.00 
   85–99 1.24 (1.20–1.29) 1.26 (1.20–1.31)
   100–109 2.00 (1.92–2.09) 2.18 (2.08–2.29)
   ≥110 3.65 (3.50–3.80) 3.83 (3.65–4.03)
Log GGT NA 1.63 (1.59–1.67)
NA, not applicable; BP, blood pressure; GGT, γ glutamyl transferase. 
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values ≥110 mg/dL had the highest hazard ratio for the inci-
dence of diabetes (men, 3.65; women, 3.83). The risk equation 
is provided in Supplementary Table 1.
Fig. 1 compares the predicted and observed risks of a diabe-
tes event at 10 years by decile of predicted risk. The predicted 
number of diabetes events in the top decile showed a pronounced 
deviation from the observed number of diabetes events, over-
estimating diabetes risk in the development cohort. However, 
the calibration plots in the validation cohort showed a predo-
minance of underestimation.
The C-statistics for the models for risk at 10 years were 0.71 
(95% confidence interval [CI], 0.70 to 0.73) in men and 0.76 
(95% CI, 0.75 to 0.78) in women in the development dataset. 
In the validation dataset, the C-statistics for the models were 
0.63 (95% CI, 0.53 to 0.73) in men and 0.66 (95% CI, 0.55 to 
0.76) in women (Fig. 1). 
Time to diabetes event is presented as Kaplan-Meier plots in 
Fig. 2. There were significant differences between groups in 
sex, age, BMI, systolic blood pressure, fasting glucose, and total 
cholesterol (log-rank test, P<0.001 for all comparisons).
Fig. 1. Calibration plots with C-statistics in the (A, B) development and (C, D) validation cohorts. Data markers represent the ob-
served event rate (position on the y-axis) in relation to the predicted event rate (position on the x-axis); dotted lines, perfect cali-
bration (i.e., observed=predicted).
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Fig. 2. Cumulative incidence of diabetes events according to (A) sex, (B) age, (C) body mass index, (D) systolic blood pressure, 
(E) fasting glucose, and (F) total cholesterol.
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DISCUSSION
We developed and validated the KDRS, which identifies people 
at high risk for diabetes based on data from regular health 
screening tests in Korea. The prevalence of diabetes in Korea 
was 8.6 in 2001 and increased to 11.0% in 2013 [1]. In addition, 
coronary revascularization such as percutaneous coronary in-
tervention and coronary artery bypass graft was performed 7 to 
10 times higher in people with type 2 diabetes mellitus (T2DM) 
than in people without diabetes in Korea [14]. However, the 
awareness rate for diabetes is 70.7%, and the lower the age, the 
lower the awareness [15]; therefore, there is a need to establish 
a diabetes risk score for the Korean population. Established 
prediction models for diabetes have been developed and vali-
dated in various population-based cohorts [16]. However, risk 
scores developed in Caucasian populations might not perform 
accurately in Asian populations because of the different bio-
logical factors associated with the onset of diabetes: lower BMI 
levels, younger ages, or earlier declines in β-cell function with 
the onset of diabetes in Asian populations [17-19]. Alth ough 
previous studies reported risk scores derived from Asian pop-
ulations, these risk scores might not accurately predict the risk 
of diabetes due to the use of cross-sectional data [20], logistic 
regression models [21], or only short-term outcomes [22-24]. 
In Korea, although discrimination was similar to KDRS, two 
risk scores for diabetes developed using different types of data-
sets, depending on the different purpose (Supplementary Table 
2) [7,8,25]. Lee et al. [7] developed diabetes score using the 
KNHANES to detect asymptomatic diabetes through simple 
questions. Lim et al. [8] developed diabetes score using cohort 
study to predict the incidence of diabetes through multiple risk 
factors. Although KDRS also developed to predict the inci-
dence of diabetes, we used long-term outcomes and survival 
regression. In addition, because the risk score developed based 
on national regular health screening test, general population 
may calculate diabetes risk score based on results of health 
screening test without any additional examination, and may 
check diabetes risk score regularly. 
The risk score was validated using a different population-
based cohort in Korea. The score exhibited moderate discrimi-
nation in the external validation cohort. However, the predict-
ed risk was underestimated in the external validation cohort. 
We used a different definition of diabetes in the development 
and validation cohorts; thus, the event rate was significantly 
higher in the validation dataset than in the development datas-
et. Moreover, differences in the definitions of clinical variables, 
such as the use of statins, may have also contributed to the un-
derestimation. However, when definition of diabetes was ap-
plied equally to a fasting blood glucose level of ≥126 mg/dL or 
medical history of diabetes in the development and validation 
cohort, the event rate was 11.8 per 1,000 person-years, similar 
to the event rate of development set, and the C-statistic were 
0.76 (95% CI, 0.63 to 0.87) for the men and 0.81 (95% CI, 0.68 
to 0.91) for the women in the validation dataset, which was 
higher than the main analysis (data not shown).
Lifestyle factors, such as smoking, and low physical activity 
are well known that increase the risk of diabetes [26,27]. How-
ever, the effect of alcohol consumption on diabetes is contro-
versial. Recent meta-analysis reported that light and moderate 
alcohol consumption was associated with a lower risk of T2DM, 
whereas heavy alcohol consumption did not affect the incidence 
of T2DM [28]. Another meta-analysis reported that moderate 
alcohol consumption reduces the risk of diabetes in women, 
but a dose-response relationship beyond the threshold. How-
ever, there was no reduction in risk in Asian populations [29]. 
In Korea, in a community-based cohort study of Korean adults, 
heavy alcohol consumption was associated with an increased 
risk of diabetes, whereas the light and moderated consumption 
was associated with a decreased risk of diabetes [30]. However, 
using KNHANES data, high-risk groups based on the alcohol-
use disorders identification test associated with a higher risk of 
diabetes in men, but not in women [31]. In addition, the pro-
portion of individuals who were abstinent with regard to alco-
hol intake was higher in women than men (34.6% and 82.1% 
for men and women, respectively). Thus, we included alcohol 
consumption in risk score only in men. Instead of alcohol con-
sumption, we included GGT in the risk score in women. GGT, 
which is a commonly used indicator of alcohol consumption 
or liver disease, may predict disease by acting as a cumulative 
biomarker of various environmental chemicals [32]. Exposure 
to several environmental irritants, such as persistent organic 
pollutants, may affect the risk for diabetes and obesity [33]. 
Additionally, a previous study reported that GGT was a predic-
tor of diabetes in the Coronary Artery Risk Development in 
Young Adult study [34]. As a result, the C-index in the external 
validation cohort was higher in women than in men (0.63 and 
0.66 for men and women, respectively). 
We also determined the appropriate range of BMI and sys-
tolic blood pressure values for increasing the risk of developing 
diabetes by evaluating the risk associated with each category of 
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variables. Obesity is one of the most important modifiable risk 
factors that can prevent diabetes. However, the effect of being 
underweight on the development of diabetes has been contro-
versial. In the National Health and Nutrition Examination Sur-
vey, the prevalence of diabetes increased as the range of obesity 
class increased [35]. However, Sairenchi et al. [36] reported 
significant associations of low (<18.5 kg/m2) and high (≥30.0 
kg/m2) BMIs with the risk of diabetes in participants aged 60 
to 79 years using data from a large Japanese cohort, whereas a 
low BMI showed no significant association in participants aged 
40 to 59 years. Our study also showed that underweight (BMI 
<18.5 kg/m2) individuals had a higher risk of diabetes than 
normal-weight (BMI 18.5 to 22.9 kg/m2) men and women, but 
this difference did not reach statistical significance. High blood 
pressure is also associated with increased risk for diabetes. In 
African Americans and Caucasians aged 35 to 54 years, higher 
blood pressure was associated with a higher risk of diabetes 
than normal blood pressure (systolic blood pressure/diastolic 
blood pressure, <120/80 mm Hg) [37]. In a community-based 
cohort study of Korean adults, people with prehypertension 
(120 to 139/80 to 89 mm Hg), stage 1 hypertension (140 to 
159/90 to 99 mm Hg), and stage 2 hypertension (≥160/100 
mm Hg) had a higher risk of developing diabetes than people 
in the normal range (<120/80 mm Hg) [38]. Additionally, the 
2017 American College of Cardiology/American Heart Asso-
ciation Task Force on Clinical Practice Guidelines suggested 
that a blood pressure target of less than 130/80 mm Hg may be 
reasonable [39]. Our study showed that the risk of diabetes in-
creased as systolic blood pressure increased; however, there was 
no significant association in men with a systolic blood pressure 
of 100 or less. 
This study has several limitations. First, the 2-hour glucose 
and HbA1c levels have played important roles in the predic-
tion of diabetes [8,40,41], although fasting glucose is the rec-
ommended screening test. We did not include the results of a 
2-hour oral glucose tolerance test or data on HbA1c levels. 
And, it is necessary to increase the accuracy of diabetes diag-
nosis by also measuring HbA1c when the fasting glucose is 
greater than 100 mg/dL in the national health screening. Sec-
ond, self-reported data on such variables as physical activity 
and alcohol intake may have introduced measurement error 
and led to the underestimation of the predictive strength of the 
risk factors. Third, we could not discriminate between type 1 
diabetes mellitus (T1DM) and T2DM. As T1DM affects about 
0.02% of the Korean population [42], our data can be attribut-
ed to people with T2DM. Fourth, a previous study reported 
that BMI should not be included in risk scores [43] and that, in 
Korea, waist circumference was a better predictor of diabetes 
than BMI [7]. However, we did not include waist circumfer-
ence. Additionally, we also did not consider triglyceride and 
high density lipoprotein cholesterol levels, which are known 
risk factors for diabetes [44]. Waist circumference, triglyceride, 
and high density lipoprotein cholesterol have been measured 
in the national health screening since 2009, and it is necessary 
to develop a prediction equation that includes these factors. Fi-
nally, dietary pattern such as red meat and sugar sweetened 
beverages intake increased risk of diabetes, while healthy diets 
such as fruit and vegetable intake decreased risk of diabetes 
[45-47]. However, we didn’t consider these effect for diabetes.
In conclusion, we developed and validated a 10-year KDRS. 
The score may help people who undergo national health screen-
ing in Korea to recognize the risk of diabetes and decide wheth-
er they should seek diabetes testing. Additionally, the score 
may be effective for delaying or preventing the onset of diabe-
tes by underscoring the need to manage the modifiable risk 
factors.
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Supplementary Table 1. Equations and examples of Korean Diabetes Risk Score
Variable
Men Women
Coefficient
Example
Coefficient
Example
Individual A Variable  coefficient Individual B
Variable  
coefficient
Age, yr 0.03429806 45 1.54341271 0.03267195 45 1.47023789 
Family history of diabetes 0.40539468 No family histo-
ry of diabetes
0 0.45270876 Family history 
of diabetes
0.45270876 
Alcohol intake: low-medium –0.08385316 NA
Alcohol intake: high 0.05447258  High of alcohol 
intake
0.05447258 NA
Former smoker 0.06879353 0.23742451 Non-smoker 0 
Current smoker 0.39075797 Current smoker 0.39075797 0.27228951 
Physical activity: medium –0.12335606 Low of physical 
activity
0 –0.06736686 Low of physical 
activity
0
Physical activity: high –0.13733219 –0.02239017 
Antihypertensive therapy 0.32880315 Taking a ACE 
inhibitor
0.32880315 0.38249871 0 
Statin therapy 0.26482252 0 0.31324724 0 
BMI <18.5 kg/m2 0.07343423 0.01107232 22.0 0 
BMI 23.0–24.9 kg/m2 0.33567685 0.32325289 
BMI 25.0–29.9 kg/m2 0.65489924 26.1 0.65489924 0.64505894 
BMI ≥30.0 kg/m2 1.25414597 1.06455937 
SBP <100 mm Hg –0.12135365 –0.17698000 110 0 
SBP 120–139 mm Hg 0.15236789 0.18910012 
SBP 140–159 mm Hg 0.25680655 150 0.25680655 0.29230610 
SBP ≥160 mm Hg 0.34104001 0.36250700 
TC ≥240 mg/dL 0.17977916 230 0 0.10497807 200 0 
FSG <70 mg/dL –0.06092024 –0.02473416 
FSG 85–99 mg/dL 0.21862977   90 0.21862977 0.22737061 
FSG 100–109 mg/dL 0.69352537 0.78101158 
FSG ≥110 mg/dL 1.29451275 1.34396826 120 1.34396826 
Log GGT, per unit NA 0.48718396   13 1.24960219 
Mean PI 1.755900 3.447782 3.079393 4.516517
Baseline survival 0.966054 0.974148 
10-Year risk of diabetes event =1–Baseline survivalexp (PI–meanPI)
=1–0.966054exp (PI –1.755900)
=1–Baseline survivalexp (PI–meanPI)
=1–0.974148exp (PI –3.079393)
Individual’s 10-year risk of a dia-
betes event
=1–0.966054exp (3.447782–1.755900) 
=0.170985
=17.1%
=1–0.974148exp (4.516517–3.079393 ) 
=0.104373
=10.4%
NA, not applicable; BMI, body mass index; SBP, systolic blood pressure; TC, total cholesterol; FSG, fasting serum glucose; GGT, γ glutamyl 
transferase; PI, prognostic index. 
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Supplementary Table 2. Summary of diabetes score in Korea
KDRS Lee et al. (2012) [7] Lim et al. (2012) [8]
Study design and sampling 
frame
Retrospective cohort study in  
random sample of Korean popula-
tion who completed a national 
health screening test 
Cross-sectional data in in random 
sample of entire Korean population
Community-based prospective  
cohort study in Korea
Data source National Health Insurance Service-
National Health Screening Cohort
Korea National Health and Nutrition 
Examination Survey
Korean Genome and Epidemiology 
Study
Duration, yr 10.8 (10.1–11.3) - 4
Age, yr, mean±SD  Men: 51.2±9.2
Women: 52.5±9.6
Normal glucose tolerance: 42.1±0.3
Impaired fasting glucose: 48.6±0.5
Undiagnosed diabetes: 51.2±0.8
51.6±8.7
How diabetes was excluded at 
baseline
Self-report of history of diabetes, 
ICD-10 code (diagnosis of diabe-
tes), fasting glucose
Self-report Fasting glucose, OGTT, HbA1c, 
self-report of use of glucose-low-
ering drugs
How diabetes was diagnosed Receiving a prescription for diabetes 
medication, fasting glucose
Fasting glucose, non-fasting glucose Fasting glucose, OGTT, HbA1c, 
self-report of use of glucose-low-
ering drugs
Statistical analysis Cox regression Logistic regression Logistic regression
Variables of risk score Age, family history of diabetes,  
alcohol intake (only in men), 
smoking status, physical activity, 
use of antihypertensive therapy, use 
of statin therapy, body mass index, 
systolic blood pressure,  
total cholesterol, fasting glucose, 
GGT (only in women)
Age, family history of diabetes,  
hypertension, waist circumference, 
smoking, alcohol intake
Age, family history of diabetes, 
smoking status, body mass index, 
hypertension, fasting glucose, 
HbA1c, HDL-C, triglyceride 
Diabetes incidence or  
prevalence
10.4 per 1,000 PY 3.6%, undiagnosed diabetes 6.9%
AROC (95% CI) Men: 0.71 (0.70–0.73)
Women: 0.76 (0.75–0.78)
0.73 0.77 (0.74–0.79)
KDRS, Korean Diabetes Risk Score; ICD-10, 10th edition of the International Classification of Diseases; OGTT, oral glucose tolerance test; 
HbA1c, glycosylated hemoglobin; GGT, γ glutamyl transferase; HDL-C, high density lipoprotein cholesterol; AROC, area under the receiver 
operating characteristic curve; CI, confidence interval; PY, person-years.
